You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TKI

Showing 51 - 75 of 1,196
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC With EGFR Mutation Trial in Mexico City (Glutamine plus L. reuteri)

Recruiting
  • Non-Small Cell Lung Cancer With EGFR Mutation
  • Glutamine plus L. reuteri
  • Mexico City, Mexico
    Instituto Nacional de Cancerologia de Mexico
May 2, 2023

Locally Advanced or Metastatic NSCLC Patients, Progressed From

Active, not recruiting
  • Locally Advanced or Metastatic NSCLC
    • Beijing, China
    • +16 more
    Dec 16, 2022

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    Lung Cancer Trial in Boston (EGF816, Gefitinib)

    Active, not recruiting
    • Lung Cancer
    • Boston, Massachusetts
      Massachusetts General Hospital
    Jan 21, 2022

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 30, 2023

    Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

    Not yet recruiting
    • Lung Cancer
    • +4 more
    • (no location specified)
    Sep 15, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guanzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 24, 2023

    Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

    Active, not recruiting
    • Renal Cell Carcinoma
    • Nivolumab
    • +2 more
    • Springdale, Arkansas
    • +33 more
    Nov 22, 2022

    NSCLC Trial (QLH11811)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    Sep 22, 2022

    CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

    Not yet recruiting
    • CML (Chronic Myelogenous Leukemia
    • (no location specified)
    Jul 27, 2022

    Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

    Recruiting
    • MMR on 12 Month
    • TKI
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 21, 2022

    Differentiated Thyroid Cancer Trial in China (AL2846 capsule)

    Recruiting
    • Differentiated Thyroid Cancer
    • AL2846 capsule
    • Guilin, Guangxi, China
    • +3 more
    Feb 27, 2023

    Eating Rate Trial in Wageningen (ultra-processed slow eating rate diet, Ultra-processed fast eating rate diet)

    Recruiting
    • Eating Rate
    • ultra-processed slow eating rate diet
    • Ultra-processed fast eating rate diet
    • Wageningen, Gelderland, Netherlands
      Wageningen University
    Nov 3, 2023

    Colorectal Tumors Trial in Wuhan (Surufatinib)

    Recruiting
    • Colorectal Neoplasms
    • Chohort 1: Surufatinib
    • +2 more
    • Wuhan, Hubei, China
      Hubei Cancer Hospital
    Nov 5, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
    Dec 7, 2021

    METAstatic Gastrointestinal Stromal Tumors (METAGIST)

    Recruiting
    • Gastro Intestinal Stromal Tumor
    • oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
    • Bordeaux, France
      Institut Bergonié, Comprehensive Cancer Center
    Dec 1, 2022

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)

    Recruiting
    • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    • Frankfurt, Germany
      Department of Medicine, Hematology and Oncology, Goethe Universi
    Sep 24, 2023

    Unresectable Hepatocellular Carcinoma Trial in Beijing (Camrelizumab, HAIC, TKI)

    Recruiting
    • Unresectable Hepatocellular Carcinoma
    • Beijing, Beijing, China
      Cancer Institute and Hospital, Chinese Academy of Medical Scienc
    Nov 22, 2021

    Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))

    Withdrawn
    • Prophylactic HQP1351 Therapy
    • Third Generation TKI
    • HQP1351( Olverembatinib dimesylate)
    • Guanzhou, China
      Department of Hematology, Nanfang Hospital, Southern Medical Uni
    Jan 16, 2023

    Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

    Active, not recruiting
    • Diarrhea
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    TKI Discontinuation in CML Patients of China

    Recruiting
    • Leukemia
    • +4 more
      • Shenzhen, Guangdong, China
        Shenzhen Second People's Hospital
      Mar 15, 2022

      Hepatocellular Carcinoma Trial in Chicago (Atezolizumab and Bevacizumab, Y90 + TKI)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • Atezolizumab and Bevacizumab
      • Y90 + TKI
      • Chicago, Illinois
        Northwestern University
      Nov 11, 2022

      Non Small Cell Lung Cancer Trial in Shanghai (Tislelizumab, Carboplatin, Pemetrexed)

      Recruiting
      • Non Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Nov 19, 2021

      Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

      Recruiting
      • Chronic Phase Chronic Myelogenous Leukemia
      • Detroit, Michigan
      • +1 more
      May 3, 2022